Biostem Technologies (BSEM) investor relations material

Executive summary

• Completed acquisition of BioTissue's Surgical and Wound assets in January 2026, diversifying business and expanding into hospital-based settings.

• Shifted commercial focus to hospital and ASC channels, reducing reliance on physician office segment and CMS reimbursement.

• Integrated BioTissue's sales force, promoted Barry Hasset to Chief Commercial Officer, and expanded commercial infrastructure.

• Published top-line results from DFU clinical trial, demonstrating BioREtain product superiority; VLU study top-line results expected mid-2026.

• Strengthened board with new Audit Committee Chairperson.

Financial highlights

• Q4 2025 revenue was $10.1 million, flat sequentially but down from $22.7 million in Q4 2024 and 55% lower year-over-year.

• Gross profit for Q4 was $9.8 million, with gross margin rising to 97% from 88% in the prior period, due to product mix shift.

• Q4 2025 GAAP net loss was ($11.3 million) or ($0.67) per share, compared to net income of $14.7 million or $0.89 per share in Q4 2024.

• Operating expenses rose to $17.3 million in Q4, driven by an $8.8 million allowance for potential uncollectible accounts from Venture Medical.

• Cash balance at year-end was $29.5 million; post-acquisition, cash and equivalents were approximately $16 million.

Outlook and guidance

• Q1 2026 revenue expected between $5 million and $6 million, reflecting hospital business stability and physician office decline.

• Hospital business expected to represent the majority of revenue in 2026, with sequential and year-over-year growth anticipated in the second half.

• Physician office revenue projected to be significantly lower in 2026 due to CMS reimbursement changes, but market expected to stabilize in H2 2026.

• Gross margins on acquired products expected at 60% during the 12-month supply agreement, rising to 80%+ after in-house manufacturing begins in 2027.

• Cash runway projected into late Q3 2026, excluding a $10 million milestone payment tied to FDA clearance.